Gene therapy BBM-P002 for Parkinson's disease safety trial
Part of Brain & nervous system clinical trials.
This trial tests a new gene therapy called BBM-P002 for Parkinson's disease. It aims to see if the treatment is safe and tolerable, and may help people with moderate to advanced Parkinson's who have had the condition for at least 5 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had Parkinson's disease for at least 5 years.
- You are on a stable, regular dose of medications like levodopa.
- You agree to delay any brain surgery for Parkinson's during the study.
- You agree to not get any vaccines during the main part of the study.
- If you are able to become pregnant, you agree to use reliable birth control for at least 52 weeks after the dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of gene therapy for Parkinson's disease. It aims to make blocking cells more responsive, improving movement control and reducing symptoms.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
This trial tests a new gene therapy delivered directly into the brain to help control Parkinson's symptoms. It is for people with advanced Parkinson's disease who still have significant movement problems despite their current medications.
This trial tests an experimental gene therapy injected directly into the brain, designed for people with Parkinson's disease who carry a specific genetic change called GBA1. The goal is to see if the treatment is safe, tolerable, and helps improve motor symptoms.
This trial tests a new gene therapy that may improve movement control in people with Parkinson's disease. It involves a one-time surgical injection into the brain and requires you to be off your usual Parkinson's medications during some assessments.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new PD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.